Our mission is to accelerate the cure for kidney cancer. We engage in patient advocacy and power research by supporting government and industry research funding, facilitating research collaborations, and offering direct financial support for clinical and laboratory researchers with promising ideas. Together, we can find the cure.
KidneyCAN Advocates for Research Funding: Here’s Why
You might not realize how important it is for the kidney cancer community to advocate in order to make progress.
What are we advocating for? Awareness? Funding? Research? Cures?
The answer is — we are advocating for all of those things. We know that awareness of kidney cancer and its impact on many lives leads to a sense of urgency, a desire for solutions. Awareness leads to advocacy, and advocacy — joining to speak as one voice — leads to funding and research. That’s how we get to cures.
2021 Kidney Cancer Town Hall: Looking Forward, Looking Back
On Thursday, January 14th, KidneyCAN hosted a 2021 Town Hall Meeting to discuss the state of kidney cancer treatments and research as we begin the New Year. This was a patient-centered event, filled with lively discussion from our doctors and the patients and caregivers in the audience.
KidneyCAN strives to give patients and caregivers the opportunity to learn from credible experts. We always want to know: What do you want to learn? What are your unmet needs?
If you missed the live event, you can watch the recording right here.
From Our Blog
Proceeds from our Rock the Cure events have been used to explore exciting approaches to generate individualized vaccines for kidney cancer patients. The approach will use fresh biopsies from kidney cancer patients to accurately represent their current cancer immune profile. The cells are then cultured and multiplied using a novel cell culture technique and can serve in the future as the basis for a patient specific whole cell or RNA vaccine. The advantage of this approach is that it not only directs the immune system to the specific mutations of the tumor, but also other over expressed common and rare normal proteins and activated retroviruses. Thus, the full repertoire of targets for the immune system will be displayed. While vaccines in the past have been met with moderate benefit at best, they are now poised to synergize with the modern immunotherapy revolution of immune checkpoint inhibitors.
My death sentence was commuted by something called RADVAX — a clinical trial in its second phase being run by Dr. Hans Hammers, a recent Johns Hopkins transplant to UT Southwestern. The trial is being funded by KidneyCAN.
Funded major projects to date include:
RADVAX investigator led immunotherapy trial for 25 advanced kidney cancer patients at UT Southwestern combining Nivolumab, Ipilimumab and SBRT.
Support of UT Southwestern’s Kidney Cancer Research Program. 1 of only 2 SPOREs (Specialized Programs of Research Excellence) for Kidney Cancer in the US.